Trial Profile
A Phase II Study of Sequential Carfilzomib, Clarithromycin (Biaxin), Lenalidomide (Revlimid), and Dexamethasone (Decadron) [Car-BiRD] Therapy for Subjects With Newly Diagnosed Multiple Myeloma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 28 Mar 2024
Price :
$35
*
At a glance
- Drugs Carfilzomib (Primary) ; Dexamethasone (Primary) ; Clarithromycin; Lenalidomide
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms CarBiRD
- 22 Mar 2024 Planned End Date changed from 1 Mar 2024 to 1 Mar 2025.
- 12 Apr 2023 Planned End Date changed from 1 Mar 2023 to 1 Mar 2024.
- 10 Apr 2022 Planned End Date changed from 1 Mar 2022 to 1 Mar 2023.